Tobira finds its public path

Tobira Therapeutics Inc. (San Francisco, Calif.) will acquire Regado Biosciences Inc. (NASDAQ:RGDO) through a reverse merger. The combined company, which will be named Tobira Therapeutics and continue to trade on NASDAQ, plans to develop treatments for liver and inflammatory diseases including non-alcoholic steatohepatitis (NASH). Tobira CEO Laurent Fischer will lead the combined entity.

Regado gained $0.15 (17%) to $1.01 on Wednesday and closed the day with a market cap of $34 million. ...